Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy

Clin Cancer Res. 2017 Sep 15;23(18):5326-5328. doi: 10.1158/1078-0432.CCR-17-1799. Epub 2017 Aug 8.

Abstract

T-cell costimulation and coinhibition can be respectively exploited by blocking and agonist mAbs. Both strategies can be synergistically combined in mouse models. Early clinical results from combinations of anti-PD-1 mAbs in conjunction with agonist anti-CD137 (4-1BB) mAbs show excellent safety and promising efficacy. Clin Cancer Res; 23(18); 5326-8. ©2017 AACRSee related article by Tolcher et al., p. 5349.

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • B7-H1 Antigen / antagonists & inhibitors*
  • Clinical Trials, Phase I as Topic
  • Drug Synergism
  • Humans
  • Molecular Targeted Therapy*
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Neoplasms / metabolism
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Treatment Outcome
  • Tumor Necrosis Factor Receptor Superfamily, Member 9 / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological
  • B7-H1 Antigen
  • CD274 protein, human
  • Programmed Cell Death 1 Receptor
  • Tumor Necrosis Factor Receptor Superfamily, Member 9